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ABSTRACT
Introduction: Preliminary data suggest that
dipeptidyl peptidase-4 (DPP-4) inhibitors may
reduce microvascular events, but there is a little
evidence to support this from adequate
real-world studies. This study aimed to
compare microvascular outcomes between
patients-prescribed vildagliptin and those
prescribed sulfonylurea (SU).
Methods: This retrospective cohort study was
conducted on a large sample from the German
electronic medical records database IMS Lifelink
Disease Analyzer. We used propensity
score-matched samples of patients prescribed
either vildagliptin or SU. Exposure was defined
as therapy (SU or vildagliptin); primary
outcomes were a diagnosis of retinopathy,
nephropathy, neuropathy, or diabetic foot
ulcer over the observation period in patients
with no previous record of these outcomes.
Secondary outcome was a composite of any
primary outcome occurring in the observation
period.
Results: In total, 16,321 patients prescribed SU
and 4481 prescribed vildagliptin met the
inclusion criteria. After propensity score
matching, each sample comprised 3015
patients. Mean age was 63.7/64.6 years for SU/
vildagliptin, respectively, with mean disease
duration of 3.2/3.1 years, and mean treatment
duration of 2.5/2.3 years. Treatment with
vildagliptin was associated with a significant
lower incidence of retinopathy [odds ratio
(OR) = 0.55, P = 0.0004], neuropathy (OR 0.71,
P = 0.0001), and composite outcome (OR 0.70,
P\0.0001). Incidences of nephropathy and
diabetic foot ulcer were lower for vildagliptin,
but not significantly so (OR 0.90, P = 0.3920;
OR 0.76, P = 0.0742, respectively). There were
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no significant differences in incident rate ratios
(all P[0.05).
Conclusion: Treatment with vildagliptin was
associated with a reduced incidence of
microvascular complications, especially
neuropathy and retinopathy, compared to
treatment with SU in this clinical practice
setting.
Funding: Novartis Pharma AG.




Diabetes mellitus is a progressive and chronic
disease which is a major healthcare problem
worldwide. According to the World Health
Organization, 347 million people worldwide
have diabetes (both types 1 and 2) [1], and the
number is estimated to rise to 592 million by
2035, as forecasted by the International
Diabetes Federation [2]. Type 2 diabetes
mellitus (T2DM) results from a combination of
insulin resistance and insulin deficiency. It is
the most prevalent type of diabetes, accounting
for 95% or more of all diabetes cases globally
[3].
Diabetes can lead to many serious
microvascular degenerative complications
(e.g., retinopathy, nephropathy, and
neuropathy) resulting into an increased risk of
morbidity and mortality and with this
significant health care system costs [4]. Hence,
while, ideally, the treatment of diabetes
demands a holistic approach that can address
various complications associated with diabetes,
the primary target of achieving an adequate
blood glucose level as measured by hemoglobin
A1c (HbA1c) level seems still essential. In fact,
in previous studies in patients with T2DM, an
association between the degree of
hyperglycemia and a high risk of
microvascular complications has been shown
[5, 6]. Several prospective observational studies
have outlined the role of intensive glucose
control in reducing the risk of microvascular
complications in diabetes [7, 8]. Some of the
important drugs that are widely used in the
treatment of T2DM are metformin,
sulfonylureas, and thiazolidinediones class of
molecules [4].
Dipeptidyl peptidase-4 (DPP-4) inhibitors
were introduced in the treatment of T2DM in
2006 [9]. DPP-4 is an endogenous
aminopeptidase enzyme which degrades
incretin hormones, namely glucagon-like
peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP). DPP-4
inhibitors impart their action by increasing
the endogenous concentrations of GLP-1 and
GIP that are released in response to food intake
[10, 11]. The increased concentration of GLP-1
and GIP lead to insulin secretion by pancreatic
b-cells, decreased glucagon secretion, and
reduction in liver glucose production. Due to
their efficacy, good tolerability, low risk of
hypoglycemia, and body-weight neutrality,
DPP-4 inhibitors have gained importance in
the treatment of T2DM [12]. Vildagliptin
(Galvus; Novartis Pharma AG) is an oral
antidiabetic agent from the DPP-4 inhibitor
class of drugs. It is indicated in Europe in the
treatment of T2DM on its own (monotherapy)
in patients inadequately controlled by diet and
exercise alone and for whom metformin is
inappropriate due to contraindications or
intolerance; together with metformin, a
thiazolidinedione or a sulfonylurea (dual
therapy); or together with a sulfonylurea and
metformin (triple therapy). Vildagliptin is also
indicated for use in combination with insulin
(with or without metformin) when diet and
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exercise plus a stable dose of insulin do not
provide adequate glycemic control [3].
Several studies have indicated importance of
sulfonylureas or insulin to reduce the risk of
microvascular complications [13]. However,
there is no adequate comparative data available
on the role of a relatively new molecule, i.e., a
DPP-4 inhibitor vildagliptin, in treating the
microvascular complications associated with
T2DM. In this study, we used real-world
evidence to evaluate the role of vildagliptin in
treating microvascular complications associated
with T2DM and compared it with sulfonylurea.
The main objectives were to evaluate the
incidence of microvascular complications of
diabetes between the two treatment groups,
i.e., vildagliptin vs. sulfonylurea, as well as, to
investigate time needed for the development of




The main objective of the study was to compare
the incidence of the defined and confirmed
microvascular event outcomes following
exposure to one of two therapies: vildagliptin
and sulfonylurea. To achieve this objective, a
retrospective cohort study design was used in
which exposure, outcome, and possible
confounding variables were measureable. Since
the source of data was longitudinal electronic
medical record (EMR), the cohorts were defined
by diagnoses and exposures recorded
historically, with outcomes tracked over the
course of the study period. As such, there was
no need for patient informed consent and
ethical committee approval according to the
German and European law.
Settings
Patients’ data was extracted from IMS Lifelink
EMR Disease Analyzer (DA), Germany. This
database captures data from German patients
who visit a representative panel of physicians
composed of both general practitioners and
specialists. The panel was constituted through
stratified sampling of physicians at national level
with annual turn-over of 10–20% of the sample.
The records of patients who visit the panel were
de-identified and sent to a central EMR database
in IMSHealth. The content of the patient records
was then coded through the appropriate coding
systems [Anatomical Therapeutic Chemical
(ATC) Classification System for drugs and the
10th revision of the International Statistical
Classification of Diseases and Related Health
Problems (ICD-10) for diagnoses]. The
information of the database is updated
monthly. Due to non-interventional nature of
the present study, it did not impose a therapy
protocol, diagnostic/therapeutic procedure, or a
visit schedule. The analyzed data was from the
period of January 2007 to December 2013.
Participants
Participants were patients with T2DM treated in
an outpatient care as per recorded in IMS
Lifelink EMR DA Germany database in the
defined study period. Inclusion criteria
included having a record of diagnosis of T2DM
before or at the time of inclusion (as defined by
ICD-10 code E11), treatment initiation by either
vildagliptin or sulfonylurea, at least 6 months of
continuous treatment (the index date was the
date of initiation on therapy), continuous
available follow-up in the database as defined
by at least one visit every 6 months, and aged
greater than 40 years.
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The exclusion criteria included a recorded
history of microvascular complications before
treatment by one of the above medications and
concurrent treatment by both vildagliptin and
sulfonylurea.
History of each microvascular complication
was considered as an exclusion criterion for
when it was analyzed as the outcome. The
exclusion criterion of previous microvascular
event was applied separately for each type of
event. For example, for the outcome of
retinopathy, patients were selected for the
analysis if they had no previous record of
retinopathy, and for the outcome of
nephropathy, patients were selected if they
had no previous history of nephropathy.
Hence, patients excluded from the analysis of
one outcome may be included in the analysis of
a different outcome. For the combined
outcome, patients were excluded if they have
a record of any previous event.
To avoid confounding between comparison
groups of vildagliptin vs. sulfonylurea, matched
samples were created using propensity score
matching (see ‘‘Statistical Analysis’’ subsection
for details).
Outcomes
The primary endpoint was defined as the first
recorded occurrence of diabetic nephropathy
(ICD-10 codes: E11.2, E14.2), diabetic
retinopathy (ICD-10 codes: E11.3, E14.3),
diabetic neuropathy (ICD-10 codes: E11.4,
14.4), and diabetic foot syndrome (DFS;
through natural language processing, as there
is no ICD-10 code for this pathology).
In addition, a combined endpoint of first
recorded occurrence of nephropathy,
retinopathy, neuropathy, or DFS was
computed. The secondary endpoint was the
time from initiation of therapy to the first
occurrence of either nephropathy, retinopathy,
neuropathy, or DFS. DFS was identified through
textual analysis of the physicians’ notes which
captured associated events, such as amputation,
gangrene, etc.
Statistical Analysis
Descriptive statistics were calculated for all
study variables and consist of number and
percentage for categorical variables, as well as
mean, median, minimum, maximum, and
standard deviation for continuous variables
with 95% confidence interval (CI).
The primary outcomes, as defined above,
were assessed by unadjusted and adjusted odds
ratios (ORs; with 95% CI), expressing the
difference in risk of microvascular events
(individual and combined) for patients
prescribed vildagliptin or sulfonylurea. CIs
were estimated using the Miettinen–Nurminen
method. Secondary outcomes
(time-to-microvascular event) were analyzed
using Kaplan–Meier survival curves and the
log-rank test. Incident rate ratios (IRR) were
also calculated for different microvascular
complications comparing two treatment
groups (vildagliptin vs. sulfonylurea).
To account for potential confounding factors
between two study groups (vildagliptin vs.
sulfonylurea), matched samples were created
using propensity score matching, i.e., the
vildagliptin and sulfonylurea groups were
selected to have similar profiles of propensity
scores. The propensity scores were derived from
the probability of treatment assignment
conditional on the following confounding
factors (covariates): age, sex, line of therapy,
HbA1c score, duration of disease (\5 years vs.
C5 years), duration of treatment, previous
hypoglycemic events, co-prescribed
medications, and number of co-morbidities.
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These confounding factors could act as
potential sources of bias in evaluating main
objectives of the study, and hence, patients
with similar demographic and clinical
characteristics in two study groups (matched
samples) were pooled. Propensity score-based
matching criteria with respect to various
confounding factors were used to derive
matched samples between two study groups.
Propensity scores were generated using a logistic
regression model and matched using a genetic
algorithm for closest matching based on
propensity scores and covariate balance. The
distribution of propensity scores and covariates
was examined by group to allow for the degree
of matching to be quantified (see Fig. 1).
A preliminary feasibility study was
conducted to determine the sample size. Based
on the data collected for the feasibility study,
we estimated the frequency of microvascular
complications (combined endpoint) for
patients prescribed sulfonylurea as 11.9%, with
a reduction of 4.1% for patients prescribed
vildagliptin, and hence, the revised sample
size requirement for the main study was 3144
patients for 95% power at the 0.01 significance
level. All calculations were performed using R
3.0.2.
RESULTS
Participants and Cohort Characteristics
To investigate incidences of microvascular
complications and time required for
occurrence of such microvascular
complications, data for two groups of patients
that have exposures to either vildagliptin or
sulfonylurea were retrieved. Data were extracted
from IMS Lifelink DA database in German
population during the study time period
(52,187 vs. 12,958 patients in vildagliptin and
sulfonylurea groups respectively). Several
inclusion and exclusion criteria were applied
(see ‘‘Methods’’ section for details) to select
patients with certain characteristics in each
study group. This led to 16,321 and 4481
patients in sulfonylurea and vildagliptin study
Fig. 1 Distribution of propensity scores for vildagliptin and sulfonylurea samples
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groups, respectively. Detailed list of number of
patients at each stage in each study group after
applying various inclusion/exclusion criteria are
mentioned in Table 1.
Patients in two cohorts (unmatched samples)
differed with respect to several demographic
and clinical characteristics, e.g., age, sex, line of
therapy, HbA1c level, duration of disease and
treatment, co-prescribed medications, and
co-morbid conditions (supporting information,
Tables S1 and S2). Matched samples contained
3015 patients in both sulfonylurea and
vildagliptin study groups. Various comparable
demographic and clinical characteristics of
patients in matched samples in both study
groups are described in Tables 2 and 3.
Incidences of Microvascular
Complications
Primary endpoint of the present investigation
was to measure the first occurrence of
microvascular complications in diabetic
patients which were assigned to vildagliptin or
sulfonylurea treatments. Particularly incidences
for retinopathy, nephropathy, neuropathy, DFS,
or composite (occurrence of any of above
complications) outcomes were measured
Table 1 Selection of participants in each study group
Variable Vildagliptin Sulfonylurea
First prescription (study window) 12,958 52,187
Age at index date above 40 years 12,637 51,492
Continuous treatment in the same practice (C1 visit each half-year during
at least 1 year before and after index date
8226 35,476
With a type II diabetes diagnosis on/before index date 6046 21,939
No insulin prescriptions at baseline/during follow-up 5938 21,511
No prescriptions of sulfonylurea and vildagliptin at the same time 4481 16,321
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between two matched sample study arms
(Table 4, data for unmatched samples are
available in supporting information, Table S3).
Incidences of each microvascular
complications, i.e., retinopathy, nephropathy,
neuropathy, DFS, or composite, appeared
higher in the sulfonylurea study arm when
compared with the vildagliptin arm (Table 4).
To enable direct comparison between study
arms, ORs based on incidences for each








Male 1731 (57.4%) 1641 (54.4%)
Female 1284 (42.6%) 1372 (45.6%)
Line of therapy
1st line 25.1% 18.6%
2nd line 52.2% 58.5%
3rd line 18.7% 16.3%
4th or higher line 3.4% 4.6%
HbA1c
N (%) available 3015 3015
Mean (SD) 7.61 (1.47) 7.64 (1.37)
Minimum 4.6 3.6
Maximum 19.0 16.1
Duration of disease (years)
Mean (SD) 3.1 (3.4) 3.2 (3.4)
Minimum 0.0 0.0
Maximum 20.4 20.9
Duration of treatment (years)
Mean (SD) 2.3 (2.6) 2.5 (2.8)
Minimum 0.0 0.0
Maximum 18.2 16.9
Previous hypoglycemic event (N, %) 19 (0.63%) 23 (0.77%)
HbA1c hemoglobin A1c, SD standard deviation
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microvascular complication for vildagliptin vs.
sulfonylurea treatments were calculated.
Treatment with vildagliptin was found to be
associated with a significantly lower incidences
of retinopathy (OR 0.55, 95% CI 0.39–0.77,
P = 0.0004), neuropathy (OR 0.71, 95% CI
0.60–0.85, P = 0.0001), and composite
outcome (OR 0.70, 95% CI 0.61–0.82,
P\0.0001; Table 5 and Fig. 2). Differences
were non-significant for nephropathy (OR
Table 3 Clinical characteristics (matched samples)
Clinical characteristic Vildagliptin Sulfonylurea
Co-prescribed medications (N, %)
Antihypertensives (C03, C07, C08, C09) 2505 (83.1%) 2472 (82.0%)
Lipid modifying agents (C10) 1424 (47.2%) 1420 (47.1%)
Other DPP-4 (A10 N excluding vildagliptin) 109 (3.61%) 305 (10.1%)
GLP-1 (A10S) 70 (2.32%) 96 (3.2%)
Metformin (A10 J) 2629 (87.2%) 2559 (85.0%)
SGLT 2 (A10P) 39 (1.3%) 25 (0.9%)
Alpha glucosidase inhibitors (A10L) 33 (1.1%) 41 (1.4%)
Glinides (A10 M) 89 (3.0%) 79 (2.6%)
Glitazone (TZD) (A10 K) 43 (1.4%) 76 (2.6%)
Insulin (A10C) 297 (9.9%) 332 (11.0%)
Co-morbid conditions (N, %)
Hypertension (I10) 2591 (86.0%) 2558 (85.0%)
Peripheral vascular disease (I739, E115, E145) 381 (12.6%) 470 (15.6%)
Hyperlipidemia (E78) 1851 (61.4%) 1852 (61.4%)
Prior stroke (I63,64) 115 (3.81%) 151 (5.01%)
Myocardial infarction (I21-23, I252) 209 (7.0%) 201 (6.67%)
Ischemic heart disease (I24,25) 822 (27.3%) 934 (31.0%)
Angina pectoris (I20) 242 (7.4%) 272 (8.3%)
Renal failure (N18, N19) 390 (13.0%) 334 (11.1%)
Depression (F32, 33) 729 (24.2%) 878 (29.1%)
Dementia (F01, F03, G30) 155 (5.2%) 230 (7.6%)
Charlson Comorbidity Score
Mean (SD) 2.32 (1.66) 2.39 (1.66)
Minimum 0 0
Maximum 13 20
GLP-1 glucagon-like peptide-1, SD standard deviation
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0.90, 95% CI 0.72–1.14, P = 0.3920) and DFS
(OR 0.76, 95% CI 0.57–1.03, P = 0.0742). No
significant differences in IRRs were found
between two treatment arms (Table 6; Fig. 3,
all P[0.05).
DISCUSSION
A retrospective cohort observational study was
carried out to investigate any advantage of the
relatively new DPP-4 inhibitors class of a drug
Table 4 Incidences of microvascular events (matched samples)
Microvascular event Vildagliptin Sulfonylurea
3015 3015
Retinopathy
Patients with no retinopathy prior to index date 2948 2934
Retinopathy during all available follow-up period (N) 54 97
Retinopathy during all available follow-up period (%) 1.8% 3.3%
Time-to-ﬁrst retinopathy diagnosis (years) 1.2 2.6
Neuropathy
Patients with no neuropathy prior to index date 2891 2919
Neuropathy during all available follow-up period (N) 144 160
Neuropathy during all available follow-up period (%) 5.0% 5.5%
Time-to-ﬁrst neuropathy diagnosis (years) 1.5 2.6
Nephropathy
Patients with no nephropathy prior to index date 2728 2708
Nephropathy during all available follow-up period (N) 256 343
Nephropathy during all available follow-up period (%) 9.4% 12.7%
Time-to-ﬁrst nephropathy diagnosis (years) 1.4 2.3
DFS
Patients with no DFS prior to index date 2965 2968
DFS during all available follow-up period (N) 80 104
DFS during all available follow-up period (%) 2.7% 3.5%
Time-to-ﬁrst DFS diagnosis (years) 1.7 2.1
Composite endpoint (any event)
Patients with no event prior to index date 2563 2553
Event during all available follow-up period (N) 366 489
Event during all available follow-up period (%) 14.3% 19.1%
Time-to-ﬁrst event diagnosis (years) 1.4 2.4
DFS diabetic foot syndrome
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vildagliptin over sulfonylurea in treating
microvascular complications associated with
T2DM.
Our investigations in the present study
indicate that treatment with vildagliptin is
associated with lower overall incidences of
microvascular events, particularly significant
were retinopathy and neuropathy, when
compared with sulfonylurea. Microvascular
complications associated with T2DM affect the
retina, nerves, and kidney leading to the
reduced quality of life of patients.
Time-to-event analysis based on the IRR
demonstrated no statistically significant
differences in time required for the occurrence
of various microvascular complications between
two study groups (vildagliptin vs. sulfonylurea).
Relevant patients’ data for the present study
were extracted from the IMS Lifelink EMR DA
database for the German population. The study
design (retrospective cohort study) prevents any
claims to have established causal effects based
on the observed associations. A further
limitation of database studies using EMR data
is the suboptimal recording of information by
physicians. However, in this study, the
assumption could be made that this
suboptimal recording affects both exposure
groups (vildagliptin vs. sulfonylurea) in the
same way, and thus, under-reporting may not
be an issue for this real-world evidence
comparison. Nevertheless, any conclusion
regarding the absolute incidence of each
microvascular complication shall be handled
with caution. In addition, the under-reporting
can potentially reduce the effect size, the
amount of which cannot be estimated from
the study data. It is likely that patients’
exposure to vildagliptin or sulfonylurea was
determined by their profile which, in its turn,
affects the development of microvascular
complications. We have tried to reduce or
Table 5 OR for the occurrence of microvascular events
for vildagliptin vs. sulfonylurea (matched samples)
Adjusted OR 95% CI P value
Composite endpoint 0.70 0.61–0.82 \0.0001
Retinopathy 0.55 0.39–0.77 0.0004
Nephropathy 0.90 0.72–1.14 0.3920
Neuropathy 0.71 0.60–0.85 0.0001
Diabetic foot syndrome 0.76 0.57–1.03 0.0742
CI conﬁdence interval, OR odds ratio
Fig. 2 Odds ratio (95% conﬁdence intervals) for the
occurrence of microvascular events for vildagliptin vs.
sulfonylurea (matched samples)
Table 6 IRRs for vildagliptin vs. sulfonylurea (matched
samples)
Adjusted IRR 95% CI P value
Composite endpoint 0.99 0.87–1.14 0.9285
Retinopathy 0.73 0.53–1.02 0.0680
Nephropathy 1.20 0.96–1.50 0.1121
Neuropathy 0.99 0.84–1.16 0.8647
Diabetic foot syndrome 1.02 0.76–1.37 0.8792
CI conﬁdence interval, IRR incident rate ratio
Fig. 3 Incident rate ratios (95% conﬁdence intervals) for
vildagliptin vs. sulfonylurea (matched samples)
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eliminate this confounding effect using
propensity scoring to generate comparable
groups between two treatments. Comparable
groups of patients with respect to age, sex,
HbA1c level, duration of disease and treatment,
and existing co-morbid conditions between two
treatments (vildagliptin vs. sulfonylurea)
ensured a high internal validity of our
findings. In addition, validity and
representativeness of the IMS Lifelink EMR DA
database have already been investigated for its
use in pharmacoepidemiological studies [14].
DPP-4 inhibitors have shown potential for
the management of T2DM, as corroborated by
conducted clinical trials that have indicated
safety and efficacy of vildagliptin and other
DPP-4 inhibitors in the treatment of T2DM
[15–20]. Vildagliptin is well-tolerated and
produces clinically meaningful reduction in
blood glucose level without promoting weight
gain or inducing hypoglycemia [21]. Recent
studies have shown advantages of vildagliptin
in T2DM treatment in elderly [22] and
overweight/obese patients [23]. The benefit of
DPP-4 inhibitors in addressing cardiovascular
risks associated with T2DM when compared
with, e.g., the metformin therapy was also
investigated in several studies [12, 24, 25].
Considering microvascular complications
associated with T2DM, role of intensive
glucose control therapies in treating such
microvascular complications has been
investigated in several trials. In the UK
Prospective Diabetes Study (UKPDS) trial
(ISRCTN75451837), it was reported that each
1% reduction in mean HbA1c with intensive
glucose therapies (sulfonylurea or insulin) was
associated with 37% reductions in risk of
microvascular complications [7]. An even more
pronounced effect with reductions of 54% in
microvascular complications was observed in
the Diabetes Control and Complications Trial
(DCCT; ClinicalTrials.gov identifier:
NCT00360815) [26]. Similar observations
regarding the benefit of intensive glucose
treatment in microvascular complications were
reported in Action in Diabetes and Vascular
Disease: Preterax and Diamicron Modified
Release Controlled Evaluation (ADVANCE) [27]
and Action to Control Cardiovascular Risk in
Diabetes (ACCORD; ClinicalTrials.gov
identifier: NCT00000620) [28] trials.
Several pilot studies were also conducted to
investigate whether relatively new classes of
DPP-4 inhibitors have any effect on
microvascular complications associated with
T2DM. A recent small (50 patients with T2DM),
placebo-controlled, double blind, crossover trial
has demonstrated that treatment with
saxagliptin (a DDP-4 inhibitor) for 6 weeks
could be advantageous in early microvascular
changes [29]. In another pilot study, treatment
with vildagliptin for 8 weeks in 47 patients with
T2DM has shown the significantly reduced
decreased albumin/creatinine ratio [30].
Similarly, vildagliptin has shown improved
healing features for chronic foot ulcers in
patients with T2DM [31]. Several pre-clinical
studies also observed the importance of DPP-4
inhibitors in treating microvascular
complications associated with diabetes [32–35].
Most of the studies on humans investigating
importance of DPP-4 inhibitors in microvascular
complications were preliminary and short-term
studies, and further large and long-term trials are
required to corroborate these findings. Our
present observational study has attempted to
fill in the gaps in establishing role of a DPP-4
inhibitor vildagliptin in treating microvascular
complications associated with T2DM by directly
comparing it with the sulfonylurea treatment.
The comparative evidence basis investigating
different available therapeutic options in
treating T2DM and its complications is sparse
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[36]. Hence, there is a high-demand of the
comparative effectiveness research between
various available treatment options for T2DM.
However, lengthy and costly clinical trials limit
such comparative effectiveness studies,
especially considering the fact that
head-to-head comparisons between different
treatments result into large number of
combinations and permutations of drugs to be
investigated. Nevertheless, real-world evidence
solutions, as has been implemented in the
present study, provide an effective alternative
for direct comparisons between different
therapeutic options available in the treatment
of T2DM and its complications based on
patients’ data extracted from real-world
settings. Such comparative effectiveness
studies based on real-world data will be one
step forward toward achieving the tailor-made,
patient-centered approach for the treatment of
a chronic disease, such as diabetes.
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